مقاله انگلیسی مدیریت COVID-19 در بیماران مبتلا به تشنج
ترجمه نشده

مقاله انگلیسی مدیریت COVID-19 در بیماران مبتلا به تشنج

عنوان فارسی مقاله: مدیریت COVID-19 در بیماران مبتلا به تشنج: مکانیسم عملکرد درمان های دارویی بالقوه COVID-19 و در نظر گرفتن تداخلات بالقوه دارو و دارو با داروهای ضد تشنج
عنوان انگلیسی مقاله: Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications
مجله/کنفرانس: تحقیقات صرع - Epilepsy Research
رشته های تحصیلی مرتبط: پزشکی، داروسازی
گرایش های تحصیلی مرتبط: ویروس شناسی، ایمونولوژی، مغز و اعصاب، داروشناسی
کلمات کلیدی فارسی: داروهای کاندید COVID-19 ، تشنج ، تداخلات دارویی-دارویی ، داروهای ضد ویروس ، داروهای تنظیم کننده سیستم ایمنی یا ضد التهاب ، NSAIDs
کلمات کلیدی انگلیسی: COVID-19 candidate drugs, Seizures, Drug-drug interactions, Antiviral drugs, Immunomodulatory or anti-inflammatory drugs, NSAIDs
نوع نگارش مقاله: مقاله پژوهشی (Research Article)
نمایه: Scopus - Master Journals List - JCR - MedLine
شناسه دیجیتال (DOI): https://doi.org/10.1016/j.eplepsyres.2021.106675
دانشگاه: Department of Pharmacology, India
ناشر: الزویر - Elsevier
نوع ارائه مقاله: ژورنال
نوع مقاله: ISI
سال انتشار مقاله: 2021
ایمپکت فاکتور: 2.208 در سال 2020
شاخص H_index: 110 در سال 2021
شاخص SJR: 0.844 در سال 2020
شناسه ISSN: 0920-1211
شاخص Quartile (چارک): Q2 در سال 2020
فرمت مقاله انگلیسی: PDF
تعداد صفحات مقاله انگلیسی: 12
وضعیت ترجمه: ترجمه نشده است
قیمت مقاله انگلیسی: رایگان
آیا این مقاله بیس است: خیر
آیا این مقاله مدل مفهومی دارد: ندارد
آیا این مقاله پرسشنامه دارد: ندارد
آیا این مقاله متغیر دارد: ندارد
کد محصول: E15421
رفرنس: دارای رفرنس در داخل متن و انتهای مقاله
نوع رفرنس دهی: vancouver
فهرست انگلیسی مطالب

Highlights


Abstract


Abbreviations


Keywords


1. Introduction


2. Mechanisms of action of COVID-19 candidate drugs


3. Potential drug-drug interactions between ASMs and COVID-19 candidate drugs


4. Potential drug interactions between ASMs and antipyretic and anti-inflammatory drugs concomitantly used in COVID-19 patients


5. Conclusion


Data availability statement


References

نمونه متن انگلیسی مقاله

Abstract


In regard to the global pandemic of COVID-19, it seems that persons with epilepsy (PWE) are not more vulnerable to get infected by SARS-CoV-2, nor are they more susceptible to a critical course of the disease. However, management of acute seizures in patients with COVID-19 as well as management of PWE and COVID-19 needs to consider potential drug-drug interactions between antiseizure drugs and candidate drugs currently assessed as therapeutic options for COVID-19. Repurposing of several licensed and investigational drugs is discussed for therapeutic management of COVID-19. While for none of these approaches, efficacy and tolerability has been confirmed yet in sufficiently powered and controlled clinical studies, testing is ongoing with multiple clinical trials worldwide. Here, we have summarized the possible mechanisms of action of drugs currently considered as potential therapeutic options for COVID-19 management along with possible and confirmed drug-drug interactions that should be considered for a combination of antiseizure drugs and COVID-19 candidate drugs. Our review suggests that potential drug-drug interactions should be taken into account with drugs such as chloroquine/hydroxychloroquine and lopinavir/ritonavir while remdesivir and tocilizumab may be less prone to clinically relevant interactions with ASMs.


 


1. Introduction


The catastrophic global pandemic of Coronavirus disease 2019 (COVID-19) has put large parts of the world on a transient standstill. COVID-19 was first discovered in December 2019 and the causative agent was a novel subtype of beta-coronaviruses, known as SARS-CoV-2 (Rothan and Byrareddy, 2020). The novel coronavirus is an enveloped non-segmented positive-sense RNA virus (Richman et al., 2016) that was transmitted to humans via zoonotic transmission, similar to its precursors, severe acute respiratory syndrome coronavirus (SARS-CoV) (Ksiazek et al., 2003) and the Middle East respiratory syndrome coronavirus (MERS-CoV) (Zaki et al., 2012). These viruses primarily affect the respiratory system, however, clinical literature also provides evidence for neuroinvasive and neurotropic properties of SARS-CoV-2 (Carod-Artal, 2020; Li et al., 2020b; Najjar et al., 2020). Neurological symptoms reported in patients with COVID-19 include febrile seizures, status epilepticus and complications including encephalopathy, cerebral haemorrhage (Asadi-Pooya, 2020; Asadi-Pooya and Simani, 2020; Carod-Artal, 2020; Yin et al., 2020). These clinical manifestations suggest that people with neurological disorders may be more vulnerable to experience severe symptoms of COVID-19 disease. However, that does not seem to be the case. The International League Against Epilepsy (ILAE) has informed that persons with epilepsy (PWE) are not likely to be more susceptible to get COVID-19 nor are they inclined to suffer through severe manifestations of SARS-CoV-2 infection (ILAE, 2020). Even if PWE are exposed to SARS-CoV-2, it is unlikely that the frequency of seizures increases (ILAE, 2020). Nevertheless, management of COVID-19 in PWE or with acute reactive seizures requires certain precautions and guidelines to avoid worsening of the condition. In particular, potential drug-drug interaction that may occur on concomitant administration of anti-seizure medication (ASM) along with the drugs for treatment of COVID-19 need to be taken into account.

  • اشتراک گذاری در

دیدگاه خود را بنویسید:

تاکنون دیدگاهی برای این نوشته ارسال نشده است

مقاله انگلیسی مدیریت COVID-19 در بیماران مبتلا به تشنج
نوشته های مرتبط
مقالات جدید
نماد اعتماد الکترونیکی
پیوندها